A Substituted Pyrrolo[2,3-d]pyrimidine as a Protein Kinase B Inhibitor
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 60/979,192, filed Oct 11, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,492,453 | Protein Kinase B Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | ||
| US 10,059,714 | Protein Kinase B Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | ||
| US 10,654,855 | Protein Kinase B Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | ||
| US 11,236,095 | Protein Kinase B Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | ||
| US 11,760,760 | Protein Kinase B Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | ||
| US 12,252,495 | Protein Kinase B Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | ||
| US 8,101,623 | A Substituted Pyrrolo[2,3-d]pyrimidine as a Protein Kinase B Inhibitor In force · High confidence | AstraZeneca AB | In force | High confidence |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.